Jemperli Sales Reached $644 Million in First Half Ahead of AnaptysBio Update
Key Facts
Financial updates involving AnaptysBio and Nakamoto center on third-quarter 2026 results, but the latest financial announcement listed in AnaptysBio’s public record dates to September 21 and covers second-quarter and transition-year results. In that statement, AnaptysBio said global Jemperli sales reached $644 million in the half ended June 30, 2026, up 34% year over year. Sales also totaled $331 million in the three months ended June 30, up 26% year over year. These figures provide context on the drug’s performance in the first half and do not describe sales for the period ended September 30. The company listed the UBS Global Biotech Conference on its events calendar for November 17, 2026, at 11:40 a.m. Eastern Time.
AnaptysBio changed its fiscal year-end on May 18, 2026, from December 31 to June 30, and began reporting quarterly results under the new calendar with the quarter ended September 30, 2026. The change places the quarter ended September 30 in the company’s new fiscal year, whereas its fiscal year had previously ended in December. In its previous financial announcement, cash, cash equivalents and investments totaled $164.1 million on June 30, 2026, compared with $211.6 million on December 31, 2025. In a Jemperli-related development, GSK announced on October 19 that the drug had been approved in the United States as the first immunotherapy for adults with locally advanced MSI-H/dMMR rectal cancer. First-half sales of $644 million, up 34% year over year, remain the latest Jemperli sales figures in the available company information.
For Quimilza, a treatment for generalized pustular psoriasis, the U.S. Food and Drug Administration set December 12, 2026, as the target date for its PDUFA action. AnaptysBio also said it expects a ruling in its dispute with GSK and Tesaro in the fourth quarter of 2026 or the first quarter of 2027, and is seeking to regain Jemperli rights as compensation. These regulatory and court dates put developments involving the drug and its rights among the company’s upcoming milestones. In market data, ANAB closed at $48.77 on November 11, 2026. NAKA closed at $6.25 in the same session.
Nakamoto’s previous results provide context on its performance ahead of the third quarter: the company reported operating revenue of $35.9 million and an operating loss of $149.1 million in the second quarter of 2026. It said the operating loss was driven mainly by goodwill impairment charges and digital asset revaluation losses. Adjusted operating income for the quarter was $7.3 million, while the company reported a net loss of $133.0 million, or $6.65 per diluted share. It also said it held 4,467 bitcoin on June 30, with a total fair value of approximately $261.5 million at quarter-end. During the second quarter, it reduced outstanding debt by approximately $45 million and extended the maturity of approximately $105 million in principal through June 30, 2027.